New malaria pill tested in humans for first time

NCT ID NCT06171113

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called GSK4024484 in 156 healthy adults to see if it is safe and how the body handles it. Researchers will also check if food affects the drug. The goal is to gather safety information before testing it in people with malaria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GSK4024484

What this could lead to

If this early study shows the drug is safe, it could lead to larger trials testing whether GSK4024484 can treat or prevent malaria.

What could go wrong

This is a very early Phase 1 trial in healthy people, not patients. The drug may prove unsafe or ineffective in later studies. Side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    Cambridge, CB2 0GG, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••